Advanced Wound & Burn Treatment
Extensive burns and full thickness skin wounds can be devastating to patients, even when treated.
Recent advances in tissue engineering have led to more complex biological skin equivalents that may yield more suitable wound treatment options for patients. These products are generally comprised of a polymer scaffold patch that is seeded with human fibroblasts and cultured in vitro prior to application. Unfortunately, these grafts are also expensive to produce, and similar to allografts, have the same immunological drawbacks.
The cell source used in cellular therapies for wound healing is an important consideration which has implications for the cost, speed of healing, and outcome of the treatments. Human keratinocytes are perhaps the optimal cell type to employ. However, autologous and allogenic keratinocytes suffer from the same drawbacks as their autologous and allogenic skin graft counterparts; i.e. secondary surgical sites and potential for rejection, respectively. Furthermore, cell therapies have complicated regulatory and financial hurdles to overcome prior to commercialization.
Thus, there is a need for ready-to-use wound healing and tissue engineering products that have high clinical efficiency, and that do not increase the risk of an immunologic response, but instead retains the bioactivity of a cellular treatment. Our product candidates satisfy this unmet need.
Features and Benefits of XCELL BIOLOGIX™ Hydrogel Product Candidate
|Patented technology accelerates wound closure and re-epithelialization and reduces wound contraction||Clinical data (animal) shows up to 20% improvement over existing approved amnion based products|
|Patented technology promotes neo-vascularization and keratinocyte proliferation in vivo; i.e., tissue regeneration||Clinical data (animal) shows up to 20% improvement over existing approved amnion based products|
|Patented technology contains solubilized mammalian amniotic membrane containing high concentrations of cell-derived cytokines, growth factors and collagen||Provides optimal cosmetic outcomes compared to other more expensive polymer scaffolds|
|Ease of use||Ready-to-use in 30 seconds, no need for thawing|
|Ease of storage||Off-the-shelf, no need for cryopreservation storage which can damage the collagen matrix|
|Ease of handling||No suturing|
|Adequate coverage of wounds||No supply issues, unlike allograft skin that is supply limited|
|Amniotic membrane tissue||Immunologically privileged (no immune response), unlike allograft skin which requires immunosuppressive drugs|
The hydrogel product candidate is under investigational use and not commercially available.